The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP‐70‐negative chronic lymphocytic leukemia

Abstract

With the addition of rituximab to fludarabine, improved clinical outcomes were obtained, and the stratification of patients by using ZAP-70 and CD38 may help clinicians offer more aggressive and/or experimental approaches to the treatment of patients with high-risk B-CLL subtypes.